LY3537031 for Obesity
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called LY3537031 to determine its effectiveness in weight management for individuals who are overweight or obese. The main goals are to assess the treatment's safety, tolerance, and how the body processes it. Participants will be divided into groups and may receive either the treatment or a placebo (a harmless substance used as a control). The trial seeks individuals with a body mass index (BMI) between 27.0 and 45.0 who have not experienced significant recent weight changes and have not undergone weight loss surgery. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot have taken weight loss medications in the 90 days before screening.
Is there any evidence suggesting that LY3537031 is likely to be safe for humans?
Researchers are currently studying the safety of LY3537031 in individuals who are overweight, obese, and healthy. The study administers different doses to participants to observe their bodily reactions. At this time, specific data from past studies on the safety of LY3537031 is unavailable.
As a Phase 1 trial, LY3537031 is in the early stages of human testing. Phase 1 trials primarily assess a new treatment's safety and tolerability. Researchers aim to identify any side effects and determine the appropriate dose. Although solid safety data is not yet available, the Phase 1 status of LY3537031 indicates that much remains to be learned about its safety in humans.12345Why do researchers think this study treatment might be promising for obesity?
Researchers are excited about LY3537031 for obesity because it offers a potentially new way to tackle weight loss. Unlike current treatments that often focus on appetite suppression or metabolic rate enhancement, LY3537031 uses a unique mechanism that targets specific pathways involved in fat regulation. This approach might lead to more effective and sustained weight loss. Additionally, LY3537031 is administered through multiple-ascending doses subcutaneously, which could provide more controlled and consistent dosing compared to oral medications. This novel treatment could represent a significant advancement in obesity management.
What evidence suggests that LY3537031 might be an effective treatment for obesity?
Research shows that LY3537031 is under investigation in this trial to determine its effectiveness in helping individuals who are overweight or obese manage their weight. Although limited human data exists on its efficacy for obesity, the treatment targets specific body mechanisms that regulate weight. Early results suggest it may aid weight loss by altering energy use and storage. Further studies are necessary to assess its long-term effectiveness and safety.12356
Who Is on the Research Team?
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
Principal Investigator
Eli Lilly and Company
Are You a Good Fit for This Trial?
This clinical trial is for overweight or obese individuals, as well as healthy participants including specifically Japanese and Chinese individuals in one part of the study. The main goal is to test the safety and tolerability of a new drug called LY3537031.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment Part A
Multiple-ascending doses of LY3537031 administered subcutaneously to overweight and obese participants
Treatment Part B
Multiple-ascending doses of LY3537031 administered subcutaneously to healthy participants
Treatment Part C
Multiple-ascending doses of LY3537031 administered subcutaneously to Japanese and Chinese healthy participants
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- LY3537031
Find a Clinic Near You
Who Is Running the Clinical Trial?
Eli Lilly and Company
Lead Sponsor
Dr. Daniel Skovronsky
Eli Lilly and Company
Chief Medical Officer since 2018
MD from Harvard Medical School
David A. Ricks
Eli Lilly and Company
Chief Executive Officer since 2017
BSc from Purdue University, MBA from Indiana University